Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators.

Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators. Abstract Text:

Nicola A Hanania,James F Donohue,Nicola A Hanania,James F Donohue,

Chronic obstructive pulmonary disease (COPD) is a treatable disease characterized by progressive airflow limitation. Prevention of disease progression, improvement of symptoms, exercise tolerance, health status, and decrease in exacerbations and in mortality are the main goals of the management of COPD. Bronchodilators play a pivotal role in the treatment of symptomatic patients with COPD. Inhaled short-acting bronchodilators are currently recommended for rescue of symptoms in patients with mild disease, whereas inhaled long-acting bronchodilators are recommended as first-line agents for maintenance therapy in patients with moderate and severe disease and those with daily symptoms. Long-acting bronchodilators improve symptoms, exercise tolerance, and health status, and reduce exacerbations in patients COPD. However, their effects on long-term decline in lung function and mortality are currently under investigation. When symptoms are not sufficiently controlled by the use of one bronchodilator, combining bronchodilators of different classes may be a more effective approach. In fact, recent evidence supports the regular use of a combination of a long-acting beta2-adrenoceptor agonist and a long-acting anticholinergic agent in patients with severe COPD. Combining a long-acting beta2-adrenoceptor agonist with an inhaled corticosteroid has also been shown to be more effective than the use of either agent alone. The use of theophylline has declined in recent years because of its narrow therapeutic index, and should be reserved as a third-line option in patients with very severe disease. Several novel bronchodilators are now in different stages of development for use alone or in combination with other agents.

Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators. Publishing Authors By Initials

NA Hanania,JF Donohue,NA Hanania,JF Donohue,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Proceedings of the American Thoracic Society

VOLUME: 4

Page Numbers: 526-34

Journal Abbreviation:

ISSN: 1546-3222

DAY: 1

MONTH: Oct

YEAR: 2007

Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101203596

Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators.

AFFILIATION: Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, 1504 Taub Loop, Houston, Texas 77030, USA. hanania@bcm.edu

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Proc Am Thorac Soc

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators Related Publications

• Analysis of order statistic filters applied to ultrasonic flaw detection using split-spectrum processing.
• Configurational probabilities for symmetric dimers on a lattice: an analytical approximation with exact limits at low and high densities.
• Coxsackie virus in urban sewage; recovery of virus in season of low incidence of reported poliomyelitis.
• Cushing's syndrome in children.
• Development of the bacterial photosynthetic apparatus.
• Differences in the pattern of presentation and treatment of proximal and distal gastric cancer: results of the 2001 gastric patient care evaluation.
• Examination of the effects of structured small group formats on medical students' problem-solving performance.
• How many guests, what sort of hosts?
• Hurricane-hit practice offers lessons in disaster planning.
• Identification of proteins involved in formaldehyde metabolism by Rhodobacter sphaeroides.
• Implication of altered proteasome function in alcoholic liver injury.
• Isoprene emission from plants: why and how.
• Kinetics of erythropoiesis. A comparison of response to anemia induced by phenylhydrazine and by blood loss.
• Laboratory studies on poliomyelitis, Toronto 1947.
• Maximum likelihood estimation of A-scan amplitudes for coherent targets in media of unresolvable scatterers.
• Medical Triage for WMD Incidents Incidents an adaptation of daily triage.
• Microbes in the energy grid.
• Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators.
• Poliomyelitis virus in urban sewage; an examination for its presence over a period of 12 months.
• Prolonged survival of human poliomyelitis virus in experimentally infected river water.
• Proteasome activation by hepatitis C core protein is reversed by ethanol-induced oxidative stress.
• Rehabilitation in ankylosing spondylitis.
• Review: transient left ventricular apical ballooning, broken heart syndrome, ampulla cardiomyopathy, atypical apical ballooning, or Tako-Tsubo cardiomyopathy.
• Rh factor.
• SYSTEMIC THERAPY WITH AMETHOPTERIN IN SQUAMOUS CARCINOMA OF THE HEAD AND NECK.
• Sarcoidosis presenting as a rib fracture.
• Social profile: assessment of validity and reliability with preschool children.
• Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis.
• Treatment of local regional disease.
• Unilateral hypersecretion of aldosterone associated with adrenal hyperplasia as a cause of primary aldosteronism.